Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.
Melissa Yan(Indiana University Health), Nasser H. Hanna(Ontario Institute for Cancer Research), Hirva Mamdani(Wayne State University), Apar Kishor Ganti(University of Nebraska Medical Center), Naomi Fujioka(University of Minnesota), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Borys Hrinczenko(Michigan State University), Salma K. Jabbour(Rutgers, The State University of New Jersey), Salah Almokadem, Greg Andrew Durm(Indiana University Health), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Lawrence Feldman(University of Illinois Chicago), Goetz Kloecker(University of Louisville)
Cited by 9
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k